LENZ Therapeutics, Inc. (LENZ)
LENZ moved a median of -0.05% 30 minutes after news, and -1.12% by the close. How LENZ actually reacts to news — the realized, point-in-time move the market made, measured across 297 labeled events over the last three years with zero look-ahead.
LENZ’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.15% | 39% | 293 |
| 30-min | -0.05% | 40% | 293 |
| 60-min | -0.71% | 39% | 293 |
| to close | -1.12% | 38% | 293 |
| Middle 50% of LENZ reactions | -1.31% to +0.90% |
|---|---|
| Median reaction (30-min) | -0.05% |
| Measured reactions | 297 |
Half of all LENZ Therapeutics, Inc. news events land between -1.31% and +0.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How LENZ reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 22 | -1.26% | 23% | -1.13% |
| Rating reiterations | 31 | -0.20% | 42% | -0.01% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how LENZ ranks against every other measured name →
That’s how LENZ usually reacts — get an email when it moves on news →Email me when LENZ moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to LENZ's baseline. Nothing else.
Recent LENZ events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (LENZ) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.33% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages LENZ Therapeutics, Inc. (LENZ) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.10% | -2.68% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating LENZ Therapeutics, Inc. (LENZ) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.18% | -4.14% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -7.48% | -10.42% | |
| LENZ Therapeutics, Inc. (LENZ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.09% | +2.94% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages LENZ Therapeutics, Inc. (LENZ) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.09% | +8.82% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against LENZ Therapeutics, Inc. (LENZ) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +1.76% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages LENZ Therapeutics, Inc. (LENZ) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.16% | +2.96% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against LENZ Therapeutics, Inc. (LENZ) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.52% | +0.63% | |
| Form 10-Q LENZ Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +9.35% | -15.86% | |
| Form 8-K LENZ Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +9.35% | -15.86% | |
| LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | +9.35% | -15.86% | |
| LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 | Press release | GlobeNewswire | +0.78% | +3.33% | |
| Moon Rabbit Appoints Amy Labb as Executive Vice President, Media | Press release | PR Web | +0.88% | +0.53% | |
| LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia | Press release | GlobeNewswire | -0.69% | -3.28% | |
| Form 8-K LENZ Therapeutics, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | -3.28% | |
| LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand | Press release | GlobeNewswire | +1.29% | -6.06% | |
| Form 8-K LENZ Therapeutics, Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -3.91% | |
| Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China | Press release | PR Newswire | -1.20% | -5.22% | |
| LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China | Press release | GlobeNewswire | -1.20% | -5.22% | |
| LENZ Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.11% | +1.71% | |
| Form 10-Q LENZ Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.43% | +4.22% | |
| Form 8-K LENZ Therapeutics, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +3.43% | +4.22% | |
| LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | +3.43% | +4.22% | |
| LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference | Press release | GlobeNewswire | +2.87% | +4.39% | |
| Form ARS LENZ Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.97% | -2.58% | |
| Form DEF 14A LENZ Therapeutics, Inc. For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | -0.97% | -2.58% | |
| Form DEFA14A LENZ Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.97% | -2.58% | |
| LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom | Press release | GlobeNewswire | -4.55% | +0.20% | |
| Form 10-K LENZ Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.98% | -1.31% | |
| Form 8-K LENZ Therapeutics, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -11.18% | -13.75% | |
| Form S-8 LENZ Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.98% | -1.31% | |
| LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -11.18% | -13.75% | |
| LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 | Press release | GlobeNewswire | +1.59% | +4.87% | |
| LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia | Press release | GlobeNewswire | +0.80% | -5.09% | |
| LENZ Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.21% | +0.34% | |
| LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign | Press release | PR Newswire | +2.68% | +14.68% | |
| LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign | Press release | GlobeNewswire | +2.68% | +14.68% | |
| Form 8-K LENZ Therapeutics, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | +0.92% | -6.79% | |
| LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates | Press release | GlobeNewswire | +0.92% | -6.79% | |
| LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East | Press release | GlobeNewswire | -0.12% | +1.85% | |
| Form 8-K LENZ Therapeutics, Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -2.77% | -12.28% | |
| LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia | Press release | GlobeNewswire | +0.34% | +1.33% | |
| LENZ Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.29% | +1.42% | |
| Form 10-Q LENZ Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.94% | +3.52% | |
| Form 8-K LENZ Therapeutics, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -2.13% | -15.47% | |
| LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -2.13% | -15.47% | |
| LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025 | Press release | GlobeNewswire | +0.39% | -1.16% | |
| Form 8-K LENZ Therapeutics, Inc. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -1.47% | -5.92% | |
| Form 8-K LENZ Therapeutics, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +2.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the LENZ section they belong to.
Where else LENZ is measured.
LENZ earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is LENZ Therapeutics, Inc.'s median reaction calculated?
Every labeled LENZ news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 297 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of LENZ's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does LENZ's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.